Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.52 |
| ▸ | CHRNG | P07510 | 3/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.52 |
| ▸ | CHRND | Q07001 | 3/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.51 |
| ▸ | KLK1 | P06870 | 2/20 | 0.51 |
| ▸ | FCER2 | P06734 | 5/20 | 0.51 |
| ▸ | MMP1 | P03956 | 4/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807932 | 1.00 | CTSL (0.58) | CTSLCTSBCTSSCHRNA1CHRNG | |
| SCHEMBL6803131 | 0.85 | MEN1 (0.60) | CTSLCTSBCTSSCHRNA1CHRNG | |
| SCHEMBL6803124 | 0.85 | MEN1 (0.60) | CTSLCTSBCTSSCHRNA1CHRNG | |
| SCHEMBL6801392 | 0.85 | CTSL (0.53) | CTSLCTSBCTSSCHRNA1CHRNG | |
| SCHEMBL6801389 | 0.85 | CTSL (0.53) | CTSLCTSBCTSSCHRNA1CHRNG | |
| SCHEMBL7134683 | 0.78 | CTSS (0.52) | CTSLCTSBCTSS | |
| SCHEMBL14486100 | 0.77 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL3838856 | 0.77 | ALDH1A1 (0.69) | — | |
| SCHEMBL21137542 | 0.76 | CTSS (0.68) | CTSLCTSBCTSS | |
| SCHEMBL21560530 | 0.75 | CHRNA1 (0.73) | CTSLCTSBCTSSCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CTSL 2677/4885CTSB 2219/4885CTSS 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.